The classical pathway is activated by C1q-mediated recognition of the target. Further activation of this pathway causes C4b and its cleavage product iC4b to accumulate in the tissues. C4b binds to C2 ...

Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this point ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

When drug development and the immune system collide we get CAR-T, checkpoint inhibitors, oncolytic vaccines, monoclonal antibodies and more. These fields have produced many therapies and garnered a ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated ...

Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...

Researchers in the United States have conducted a study showing that activation of the complement system is specifically implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), ...

Duke University Medical Center researchers have discovered that a seemingly mild "insult" to the brain could sensitize neurons to attack by immune system proteins that are otherwise protective ...

Please provide your email address to receive an email when new articles are posted on . In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed ...

DURHAM, N.C. -- Duke University Medical Center researchers have discovered that a seemingly mild "insult" to the brain could sensitize neurons to attack by immune system proteins that are otherwise ...